Skip to main content

Table 1 Correlation between IRF-2 and clinicopathologic characteristics

From: IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer

  Total IRF-2 expression P value
Low (35) High(37)
Sex
 Male 55 28 (50.9) 27 (49.1) 0.483
 Female 17 7 (41.2) 10 (58.5)
Age(y)
 < 60 34 16 (47.1) 18 (52.9) 0.803
 ≥ 60 38 19 (50.0) 19 (50.0)
Histological grade
 G1–2 32 18 (56.3) 14 (43.7) 0.460
 G3 40 19 (47.5) 21 (52.5)
Invasive depth
 Mucosa to muscularis propria 21 9 (42.9) 12 (60.6) 0.150
 Adventitia to adjacent structure 51 22 (56.4) 17 (43.6)
Lymph nodes metastasis
 ≤ 2 regions 33 13 (39.4) 20 (30.77) 0.407
 > 2 regions 39 31 (60.78) 20 (39.22)
Distant metastasis
 Yes 8 6 (75.0) 2 (25.0) 0.146
 No 64 29 (45.3) 35 (54.7)
Position
 Antrum and gastric angle 32 14 (43.8) 18 (56.3) 0.460
 Others 40 21 (52.5) 19 (47.5)
Size
 < 4 cm 27 13 (48.1) 14 (51.9) 0.951
 ≥ 4 cm 45 22 (48.9) 23 (51.1)
TNM stage
 I, II 28 12 (42.9) 16 (57.1) 0.436
 III, IV 44 23 (52.3) 21 (47.7)
  1. Fisher’s exact test for distant metastasis; χ2 test for all other analyses